HSBC Holdings
VNDA icon

HSBC Holdings’s Vanda Pharmaceuticals VNDA Stock Holding History

HSBC Holdings’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$261K Buy
38,855
+3,144
+9% +$24.2K ﹤0.01% 2509
2025
Q4 		$321K Sell
35,711
-35,535
-50% -$196K ﹤0.01% 2509
2025
Q3 		$354K Buy
71,246
+4,692
+7% +$21.7K ﹤0.01% 2269
2025
Q2 		$319K Buy
66,554
+9,960
+18% +$43.6K ﹤0.01% 2401
2025
Q1 		$259K Buy
56,594
+8,545
+18% +$39.8K ﹤0.01% 2463
2024
Q4 		$229K Buy
48,049
+21,584
+82% +$104K ﹤0.01% 2646
2024
Q3 		$124K Buy
+26,465
New +$142K ﹤0.01% 2758
2024
Q1 		– Sell
-29,207
Closed -$123K – 3251
2023
Q4 		$123K Buy
+29,207
New +$118K ﹤0.01% 2564
2023
Q1 		– Sell
-10,548
Closed -$77.6K – 3071
2022
Q4 		$77.6K Buy
+10,548
New +$103K ﹤0.01% 2935
2022
Q3 		– Sell
-12,201
Closed -$132K – 3292
2022
Q2 		$132K Sell
12,201
-1,188
-9% -$12.3K ﹤0.01% 2987
2022
Q1 		$153K Buy
+13,389
New +$176K ﹤0.01% 3047

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

HSBC Holdings's VNDA Position: Q1 2026 in Review

HSBC Holdings increased its Vanda Pharmaceuticals (VNDA) stake by 8.8% in Q1 2026, buying an estimated $24.2K and bringing the position to 38,855 shares worth $261K. The position accounts for ﹤0.01% of the portfolio, ranked #2509.

HSBC Holdings first reported a position in VNDA in Q1 2022 and has held it in 11 quarters since. The position peaked at $354K in Q3 2025. 170 funds tracked by Wall St. Rank hold VNDA as of Q1 2026.

  • HSBC Holdings held 38,855 shares of Vanda Pharmaceuticals worth $261K as of Q1 2026.
  • HSBC Holdings bought 3,144 Vanda Pharmaceuticals shares in Q1 2026, an estimated $24.2K.
  • Vanda Pharmaceuticals made up ﹤0.01% of HSBC Holdings's portfolio in Q1 2026, its #2509 holding.
  • HSBC Holdings first reported a position in Vanda Pharmaceuticals in Q1 2022 and has held it in 11 quarters since.
  • HSBC Holdings's Vanda Pharmaceuticals position peaked at $354K in Q3 2025.
  • 170 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2026.

Based on HSBC Holdings's 13F filing for Q1 2026, filed 30 Apr 2026.